Guidance on using tocilizumab for juvenile idiopathic arthritis.
Medical care for rheumatic disease in children has been supported by advances in rheumatology. In the past few years and based on knowledge about cytokines, particularly marked advances have been made in treatments using biological products. The fact that patients showed a marked response to treatment with biological products also provided uniform direction to treatment choice, which had previously been chaotic. On the other hand, biological products inhibit the action of physiologically essential substances, such as inflammatory cytokines or their receptors. This led to concerns about the risk of fatal or life-threatening adverse reactions, and rheumatologists are now required to take a disciplined approach to the use of these products. Thus, we sincerely hope that this guidance on using tocilizumab for juvenile idiopathic arthritis serves as a desk reference for pediatric rheumatologists and other healthcare professionals treating children with rheumatic diseases by biological drugs.